Skip to content

Medical Records Based Real-World Study of Cetuximab in Combination with FOLFIRI Regimen as First-Line Chemotherapy and Subsequent Cetuximab-based Maintenance Therapy for the Maintenance Treatment of Patients with RAS and BRAF Wild-Type Unresectable Metastatic Colorectal Cancer

Real-World Study of Cetuximab in Combination with FOLFIRI Regimen as First-Line Chemotherapy and Subsequent Cetuximab-Based Maintenance Therapy for the Maintenance Treatment of Patients with RAS and BRAF Wild-Type Unresectable Metastatic Colorectal Cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040940
Enrollment
Unknown
Registered
2020-12-16
Start date
2020-12-02
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Maintenance group:Nil

Sponsors

Medical Oncology Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects must meet all of the following criteria to be included in this retrospective study: A. Aged 18 to 75 years, male or female; B. histologically diagnosed adenocarcinoma of the colon or rectum; C. metastatic disease (not amenable to curative resection); D. RAS and BRAF wild-type; E. complete imaging assessment data: including baseline and PD data confirmed by CT or MRI; F. treated with the study's specified treatment regimen.

Exclusion criteria

Exclusion criteria: Subjects will not be included in this study if any of the following conditions are met: A. Other concomitant anti-tumor treatment; B. History of other malignant tumors except CRC within the past 5 years, except for cured cervical carcinoma in situ, basal skin cancer or squamous cell carcinoma; C. Participating in other clinical trials of anti-tumor drugs during the treatment period.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival;Adverse Events;Failure-free survival;

Secondary

MeasureTime frame
Overall Survival;Objective response rate;Quality of Life;Compliance;Disease control rate;

Countries

China

Contacts

Public ContactXiaoyan Lin

Fujian Medical University Union Hospital

13950482366@qq.com+86 133659107893

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026